Shares of Vical Incorporated (NASDAQ:VICL) have been assigned an average broker rating score of 1.50 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company.
Brokers have set a twelve-month consensus price target of $4.20 for the company and are forecasting that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Vical an industry rank of 59 out of 256 based on the ratings given to related companies.
Several equities analysts have issued reports on the company. HC Wainwright set a $4.00 target price on Vical and gave the company a “buy” rating in a research note on Tuesday, October 30th. Zacks Investment Research lowered Vical from a “buy” rating to a “hold” rating in a research note on Saturday.
VICL opened at $1.14 on Friday. Vical has a 1 year low of $1.00 and a 1 year high of $1.92. The stock has a market capitalization of $25.09 million, a price-to-earnings ratio of -1.13 and a beta of 0.65.
Vical (NASDAQ:VICL) last posted its earnings results on Monday, October 29th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.08. Vical had a negative return on equity of 31.61% and a negative net margin of 300.44%. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.18 million. As a group, equities research analysts expect that Vical will post -0.85 EPS for the current fiscal year.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.
Featured Story: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.